tetano
Editor, Senior Moderator
Viruses
. 2022 Feb 21;14(2):446.
doi: 10.3390/v14020446.
Prevalence and Clinical Impact of Coinfection in Patients with Coronavirus Disease 2019 in Korea
Seri Jeong[SUP] 1 [/SUP], Nuri Lee[SUP] 1 [/SUP], Yeeun Park[SUP] 1 [/SUP], Jaehong Kim[SUP] 1 [/SUP], Kibum Jeon[SUP] 2 [/SUP], Min-Jeong Park[SUP] 1 [/SUP], Wonkeun Song[SUP] 1 [/SUP]
Affiliations
Abstract
Coinfection rates with other pathogens in coronavirus disease 2019 (COVID-19) varied during the pandemic. We assessed the latest prevalence of coinfection with viruses, bacteria, and fungi in COVID-19 patients for more than one year and its impact on mortality. A total of 436 samples were collected between August 2020 and October 2021. Multiplex real-time PCR, culture, and antimicrobial susceptibility testing were performed to detect pathogens. The coinfection rate of respiratory viruses in COVID-19 patients was 1.4%. Meanwhile, the rates of bacteria and fungi were 52.6% and 10.5% in hospitalized COVID-19 patients, respectively. Respiratory syncytial virus, rhinovirus, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans were the most commonly detected pathogens. Ninety percent of isolated A. baumannii was non-susceptible to carbapenem. Based on a multivariate analysis, coinfection (odds ratio [OR] = 6.095), older age (OR = 1.089), and elevated lactate dehydrogenase (OR = 1.006) were risk factors for mortality as a critical outcome. In particular, coinfection with bacteria (OR = 11.250), resistant pathogens (OR = 11.667), and infection with multiple pathogens (OR = 10.667) were significantly related to death. Screening and monitoring of coinfection in COVID-19 patients, especially for hospitalized patients during the pandemic, are beneficial for better management and survival.
Keywords: COVID-19; SARS-CoV-2; coinfection; mortality; prevalence; resistance.
. 2022 Feb 21;14(2):446.
doi: 10.3390/v14020446.
Prevalence and Clinical Impact of Coinfection in Patients with Coronavirus Disease 2019 in Korea
Seri Jeong[SUP] 1 [/SUP], Nuri Lee[SUP] 1 [/SUP], Yeeun Park[SUP] 1 [/SUP], Jaehong Kim[SUP] 1 [/SUP], Kibum Jeon[SUP] 2 [/SUP], Min-Jeong Park[SUP] 1 [/SUP], Wonkeun Song[SUP] 1 [/SUP]
Affiliations
- PMID: 35216039
- DOI: 10.3390/v14020446
Abstract
Coinfection rates with other pathogens in coronavirus disease 2019 (COVID-19) varied during the pandemic. We assessed the latest prevalence of coinfection with viruses, bacteria, and fungi in COVID-19 patients for more than one year and its impact on mortality. A total of 436 samples were collected between August 2020 and October 2021. Multiplex real-time PCR, culture, and antimicrobial susceptibility testing were performed to detect pathogens. The coinfection rate of respiratory viruses in COVID-19 patients was 1.4%. Meanwhile, the rates of bacteria and fungi were 52.6% and 10.5% in hospitalized COVID-19 patients, respectively. Respiratory syncytial virus, rhinovirus, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans were the most commonly detected pathogens. Ninety percent of isolated A. baumannii was non-susceptible to carbapenem. Based on a multivariate analysis, coinfection (odds ratio [OR] = 6.095), older age (OR = 1.089), and elevated lactate dehydrogenase (OR = 1.006) were risk factors for mortality as a critical outcome. In particular, coinfection with bacteria (OR = 11.250), resistant pathogens (OR = 11.667), and infection with multiple pathogens (OR = 10.667) were significantly related to death. Screening and monitoring of coinfection in COVID-19 patients, especially for hospitalized patients during the pandemic, are beneficial for better management and survival.
Keywords: COVID-19; SARS-CoV-2; coinfection; mortality; prevalence; resistance.